Explore.Target.Build.

What nature has kept secret for millions of years, we can now uncover in a single high-throughput experiment.

Our technology harnesses the power of genetics and AI to learn the biophysical parameters governing protein function.

Our team

Emilio Erazo-FischerChief Business Officer

Neuroscientist, Operating Partner at Asabys Partners and former Director of Global BD&L at Boehringer Ingelheim"building stimulating relationships with pharma and biotech to maximize the transformative potential of our technology"

Pilar CasadoChief Financial Officer

Business Administration graduate, former Deloitte auditor and La Perla EMEA CFO and Business Partner; 7+ years serving as CFO for biotech startups

Victoria MalavéOffice Administrator

Business Administration specialist with Human Resources experience in fast-paced industries"a great privilege to be part of the ALLOX family and support the team to push scientific boundaries"

Sol AdaglioResearch Associate

Biotechnologist specialized in molecular and microbiology"driven by the opportunity to apply my experience in biotechnology to research that has the potential to reshape healthcare"

Júlia DomingoCEO & co-founder

Biologist, bioinformatician and coinventor of the ALLOX experimental platform“proud to realize the revolutionary potential of our technology and test the core thesis of our research in the clinic”

André FaureCDO & co-founder

Engineer, computational biologist and coinventor of the ALLOX computational platform“passionate about working on truly disruptive technology at the intersection between AI and biology”

Cristina LorcaResearch Associate

Pharmacist specialized in biotechnology, molecular and cell biology"excited to combine cutting-edge molecular biology with innovative drug development strategies in a team that's passionate about making a difference"

Youssef MansourResearch Associate

Pharmacist turned protein scientist with a passion for macromolecular design

Pablo BaezaCSO & co-founder

Computational biochemist, data scientist and deep mutagenesis guru“the coolest thing about what we’re doing is the potential it has to improve the lives of millions of patients”

Ben LehnerChief Scientific Advisor & co-founder

Head of Generative and Synthetic Genomics, Wellcome Sanger Institute; ICREA Professor, CRG and Fellow of the Royal Society“we’re going beyond what we can do in academia and having a lot of fun at the same time”

Mireia SeumaSenior Scientist

Biochemist and biotechnologist with extensive experience in high-throughput mutagenesis techniques"on a mission to innovate at ALLOX and scale up discovery of allosteric sites from tens to hundreds to thousands"

We are a team of explorers and builders passionate about revolutionising drug discovery.

Boldness

Ingenuity

Determination

Teamwork

Openness

Fairness

Join us

At ALLOX the success of our revolutionary scientific approach is as important to us as our mission to create a healthy, honest and respectful culture, both internally and with our partners.

We believe that — as in other living systems — team robustness and evolvability are a consequence of diversity, and that individuals thrive when they’re empowered with freedom and responsibility.

If you’re excited about the prospect of working with us, get in touch!

News

Team Update: Emilio Erazo-Fischer and Mireia Seuma join ALLOX

Emilio, as Chief Business Officer, will identify and pursue strategic partnerships and deals to advance the company's pipeline and technology. Miriea joins as Senior Scientist to scale up the discovery of allosteric sites.

2024-12-19|NEWS

The surprisingly simple genetic architecture of protein stability

In research published in Nature, André Faure and Professor Ben Lehner – co-founders of ALLOX – have discovered that the impact of mutations on protein stability is more predictable than previously thought.

2024-10-23|NEWS COVERAGE

Júlia Domingo, CEO of ALLOX, interviewed by El·lipse magazine

Júlia explains how the company was born at the CRG, how the technology they developed works, and what its future holds.

2024-07-09|NEWS COVERAGE

Get in touch

For all enquiries, send us a message here or email us at hello@allox.bio. We look forward to hearing from you!

Name*

E-mail*

Content*

Investors

This company is capitalized by INNVIERTE, AN INVESTMENT PROGRAM OF CDTI, E.P.E.

Grants

Grant PTQ2023-013021 awarded by MCIU/AEI/10.13039/501100011033

Parc Científic de Barcelona

C/Baldiri Reixac 4-8 (Torre R),

08028 Barcelona